Patients With Newly Diagnosed Multiple Sclerosis More Likely to Have Impaired Cognitive Performance
Compared to the general population, patients with newly diagnosed MS/CIS are more likely to have impaired cognitive function.
Multiple Sclerosis
2011 to 2017 Saw Increase in Spending on DMTs for MS
From 2011 to 2017, there was an increase in gross annual expenditures on multiple sclerosis (MS) disease-modifying therapies (DMTs), with increased spending mainly driven by increases in per-prescription costs.
Risk for Disability Worsening Increased for MS With Comorbid Depression
The risk for disability worsening is increased for individuals with multiple sclerosis (MS) and comorbid depression, according to a study published in Neurology.
MENACTRIMS Guidelines for Multiple Sclerosis Updated
In a revised 2019 guideline, updated recommendations from the Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS) are presented for the diagnosis and treatment of multiple sclerosis (MS).
Economic Impact of Multiple Sclerosis Linked to Fatigue
Multiple sclerosis seems to prevent individuals from realizing their full potential at home and work, with fatigue being overwhelmingly identified as the cause, according to preliminary findings presented at ECTRIMS 2019.
First Diagnostic Consultation Factors That May Influence Satisfaction in Patients With MS
Limited data are available regarding the satisfaction of patients with MS with their first diagnostic consultation (FDC). The goal of the current retrospective study was to identify FDC factors that may influence patient satisfaction.
AAN Issues Guideline Update for Immunization in Patients With MS
AAN has issued a practice guideline update for vaccine-preventable infections and immunizations for individuals with multiple sclerosis (MS). A subcommittee of the AAN — tasked with developing, disseminating and implementing these guidelines — found improvements and additions to the recommendations previously issued in 2002.
Prices Spike for Drugs Used to Treat Multiple Sclerosis
Review of Medicare claims from 2006 to 2016 show 10.2-fold and 7.2-fold hikes in pharmaceutical and out-of-pocket spending, respectively.
Comorbidities in Multiple Sclerosis: Effects on DMTs, the Treatment Team, and More
Having a higher burden of comorbidities is associated with greater disability progression and lower QoL, as well as increased healthcare utilization and mortality.
-
Loading...
-
Loading...
Next post in Medicine
